LOS ANGELES–(BUSINESS WIRE)–Schall law firma national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM) for violating securities laws.
The investigation aims to determine whether the Company has made false and/or misleading statements and/or has failed to disclose relevant information to investors. Outset provided guidance for the second quarter of 2022 in a June 13, 2022 press release. The company announced that it had “implemented a shipping hold on the distribution of its system of Tablo hemodialysis for home use pending Food and Drug Administration (“FDA”) review and clearance of a 510(k) the company submitted for changes made since the original March 2020 clearance of the ‘device. Based on this news, Outset shares fell more than 34% on June 14, 2022.
If you are a shareholder who has suffered a loss, Click here to participate.
We also encourage you to contact Brian Schall of Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us via the firm’s website at www.schallfirm.comor by e-mail to email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to do nothing, you can remain an absent member of the group.
Schall Law Firm represents investors worldwide and specializes in securities class action and shareholder rights litigation.
This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.